Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
For years, doctors treating obesity faced one big problem. They had no early sign to indicate whether a patient was heading toward real weight loss. That guesswork may finally have an answer. Fresh data from the OASIS 4 trial show that fast early responders to the Wegovy pill go on to lose far more weight by the end of treatment.
Almost 29% of trial participants qualified as early responders. These patients lost at least 10% of their body weight by week 16. On average, this group shed 13.2% within those first four months. By week 64, they reached a total mean weight loss of 21.6%.
Even patients who missed that early marker still did well. They lost a clinically meaningful 11.5% by the trial’s end. Both groups crossed into territory that doctors consider significant. So slower starters still came out ahead in a meaningful way.
The physical function data adds another important layer. Among patients who started with poor mobility, 77.3% on oral semaglutide hit meaningful improvements in function scores. These scores tracked real daily abilities: bending, standing longer, and keeping up with normal activity. Only 42.9% of placebo recipients reached that same bar.
That gap nearly doubles the responder rate. It matters most for patients whose weight already limits daily movement. Furthermore, patients with poor baseline function lost similar weight to the overall trial group. Their mobility challenges did not blunt the drug’s metabolic effect.
Oral semaglutide 25 mg targets GLP-1 receptors in the hypothalamus and gut. It cuts appetite, slows gastric emptying, and builds fullness after meals. It acts directly on the body’s hunger signals. The FDA has approved it for weight management in adults with obesity or overweight with at least one related health condition.
Novo Nordisk also presented the ORION indirect treatment comparison at the congress. This placed oral semaglutide 25 mg next to orforglipron 36 mg, a rival oral GLP-1 drug. Oral semaglutide produced greater mean weight loss. On top of that, orforglipron carried about 14 times higher odds of patients quitting due to gut side effects.
Long-term adherence drives long-term results in obesity care. That tolerability gap, therefore, carries serious clinical weight. Patient preference data from the OPTIC study backed this up further. A full 84% of respondents chose a profile matching oral semaglutide over orforglipron.
In the primary OASIS 4 results, adults on the Wegovy pill lost an average of 17% of body weight. The placebo group lost just 2.7%. Gastrointestinal side effects showed up most often but stayed mild to moderate. They also faded as treatment continued, consistent with the broader GLP-1 drug class.
Obesity is a chronic disease rooted in genetics, environment, and biology. A four-month response marker now gives clinicians a firm anchor for early treatment talks. It supports dose escalation decisions and realistic goal-setting with patients. Consequently, this data moves obesity care one step closer to the precision it has long deserved.
